Gary M Cohen Net Worth

The estimated Net Worth of Gary M Cohen is at least $4.53 million dollars as of 14 November 2018. Gary Cohen owns over 3,053 units of Perrigo plc stock worth over $543,073 and over the last 21 years Gary sold PRGO stock worth over $3,991,744.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gary Cohen PRGO stock SEC Form 4 insiders trading

Gary has made over 53 trades of the Perrigo plc stock since 2003, according to the Form 4 filled with the SEC. Most recently Gary exercised 3,053 units of PRGO stock worth $120,960 on 14 November 2018.

The largest trade Gary's ever made was exercising 108,973 units of Perrigo plc stock on 5 November 2004 worth over $2,743,940. On average, Gary trades about 9,449 units every 31 days since 2003. As of 14 November 2018 Gary still owns at least 20,317 units of Perrigo plc stock.

You can see the complete history of Gary Cohen stock trades at the bottom of the page.

What's Gary Cohen's mailing address?

Gary's mailing address filed with the SEC is , , , , .

Insiders trading at Perrigo plc

Over the last 11 years, insiders at Perrigo plc have traded over $21,020,805 worth of Perrigo plc stock and bought 592,512 units worth $38,708,035 . The most active insiders traders include Jeffrey C Smith, Gary M Cohen et Joseph C Papa. On average, Perrigo plc executives and independent directors trade stock every 11 days with the average trade being worth of $156,424. The most recent stock trade was executed by Ronald Craig Janish on 26 August 2024, trading 13,000 units of PRGO stock currently worth $382,200.

What does Perrigo plc do?

perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).

Complete history of Gary Cohen stock trades at Becton Dickinson & Co et Perrigo plc

Perrigo plc executives and stock owners

Perrigo plc executives and other stock owners filed with the SEC include:

• Murray Kessler,
  President, Chief Executive Officer, Director
• Raymond Silcock,
  Chief Financial Officer, Executive Vice President
• Murray S. Kessler,
  CEO, Pres & Director
• Todd Kingma,
  Executive Vice President, General Counsel, Company Secretary
• James Dillard,
  Executive Vice President, Chief Scientific Officer
• Svend Andersen,
  Executive Vice President, President - Consumer Healthcare International
• Sharon Kochan,
  Executive Vice President, President - RX Pharmaceuticals
• Raymond P. Silcock,
  CFO, Principal Accounting Officer & Exec. VP
• Svend Andersen,
  Exec. VP & Pres of Consumer Healthcare International
• Richard S. Sorota,
  Exec. VP & Pres of Consumer Self-Care Americas
• Todd W. Kingma,
  Exec. VP, Gen. Counsel & Sec.
• James E. Dillard III,
  Exec. VP & Pres of Consumer Self-Care Americas
• Rolf Classon,
  Independent Director
• Donal O'Connor,
  Independent Director
• Jeffrey Kindler,
  Independent Director
• Theodore Samuels,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Bradley Alford,
  Independent Director
• Adriana Karaboutis,
  Independent Director
• Erica Mann,
  Independent Director
• Bradley Joseph,
  Vice President Global Investor Relations
• Katherine Doyle,
  Director
• Rich Sorota,
  Executive Vice President and President - Consumer Self-Care Americas
• Grainne Quinn,
  Executive Vice President, Chief Medical Officer
• Ronald Janish,
  Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer
• Thomas Farrington,
  Executive Vice President, Chief Information Officer
• Robert Willis,
  Chief Human Resource Officer, Executive Vice President
• Kyle L. Hanson,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Alison Ives,
  Exec. VP & Chief Scientific Officer
• Eduardo Guarita Bezerra,
  Exec. VP & CFO
• Mary Reilly-Brest,
  Director of Global Organizational and Human Resource Devel.
• Thomas M. Farrington,
  Chief Information Officer & Exec. VP
• Shannon Hukill,
  Sr. Director of Technical Operations
• Ronald C. Janish,
  Chief Transformation Officer and Exec. VP of Global Operations & Supply Chain
• Patrick Lockwood Taylor,
  CEO
• Paul Weninger,
  EVP, Quality Operations
• James R Michaud,
  EVP, Chief HR Officer
• John T Hendrickson,
  EVP Global Operations & Supply
• Gary M Cohen,
  Director
• John Wesolowski,
  EVP, President Rx
• Michael J Jandernoa,
  Director
• Judy L Brown,
  Executive VP & CFO
• Laurie Brlas,
  Director
• Jeffrey C Smith,
  Director
• Triona Schmelter,
  EVP & President CSCA
• Uwe Roehrhoff,
  CEO
• Ronald Winowiecki,
  CFO
• David Ball,
  EVP & CBDO
• Jacqualyn A Fouse,
  Director
• Ellen Randi Hoffing,
  Director
• Louis Yu,
  Executive VP Global Quality
• Shlomo Yanai,
  Director
• Marc Coucke,
  Executive VP & GM
• Michael Robert Stewart,
  Sr. VP Global Human Resources
• Joseph C Papa,
  President and CEO
• Gary K Jr Kunkle,
  Director
• Herman Jr Morris,
  Director
• Ben Zion Zilberfarb,
  Director
• Ran Gottfried,
  Director
• Jatin Shah,
  Sr VP & Chief Scientific Offic
• Scott F Jamison,
  
• David T Gibbons,
  Director
• Douglas Boothe,
  EVP & GM Perrigo Pharma
• Jeffrey Needham,
  EVP, President CHC Americas
• Orlando D Ashford,
  Director
• Alison Ives,
  EVP & Chief Scientific Officer
• Kyle Hanson,
  EVP & General Counsel
• Eduardo Guarita Bezerra,
  EVP & Chief Financial Officer
• Albert Manzone,
  Director
• Julia M Brown,
  Director